Medtronic (MDT) reported strong first-quarter fiscal 2025 results, with revenue reaching $8.58 billion, an 8.4% year-over-year increase that surpassed the Zacks Consensus Estimate of $8.37 billion by 2.5%. Earnings per share (EPS) for the quarter were $1.26, exceeding the consensus estimate of $1.23 by 2.44% and up from $1.23 a year prior. The company's stock has outperformed the broader market, returning +3.5% over the past month compared to the S&P 500's +2.5% gain, reflecting positive investor response to the earnings beat.
Medtronic (MDT) delivered a strong first quarter for fiscal 2025, with headline figures surpassing Wall Street expectations. The company reported revenue of $8.58 billion, an 8.4% year-over-year increase, which represents a 2.5% positive surprise over the consensus estimate. Similarly, EPS of $1.26 beat expectations by 2.44%. This outperformance was primarily driven by robust growth in key worldwide segments, notably Cardiovascular, which grew 9.3% YoY to $3.29 billion, and Diabetes, which saw an 11.4% YoY increase to $721 million. However, a detailed look at the metrics reveals underlying weakness, particularly in the U.S. market, where total revenue of $4.22 billion missed the analyst average estimate of $4.27 billion. Specific divisions within Neuroscience also underperformed, with U.S. Specialty Therapies and Cranial & Spinal Technologies both missing estimates, and the worldwide Specialty Therapies segment posting a 1.5% YoY revenue decline. While the stock's recent 3.5% gain has outpaced the S&P 500, reflecting positive sentiment from the headline beat, the Zacks Rank of #3 (Hold) and the mixed segment performance suggest a more nuanced outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
